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Abstract
Background: Therapeutic strategies for xerostomia, regardless of etiology, have so far not had definitive or clearly 
effective results. Objectives. To systematically revise the latest scientific evidence available regarding the treat-
ment of dry mouth, regardless of the cause of the problem. 
Material and Methods: The literature search was conducted in March 2015, using the Medline and Embase data-
bases. The “Clinical Trial”, from 2006 to March 2015, was carried out in English and only on human cases. The 
draft of the systematic review and assessment of the methodological quality of the trials was carried out following 
the criteria of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and the “Oxford 
Quality Scale”. 
Results: Finally, a total of 26 trials were identified that met the previously defined selection and quality criteria; 
14 related to drug treatments for dry mouth, 10 with non-pharmacological treatment and 2 with alternative treat-
ments. 
Conclusions: Pilocarpine continues to be the best performing sialogogue drug for subjects with xerostomia due 
to radiation on head and neck cancer or diseases such as Sjogren’s Syndrome. For patients with dry mouth caused 
solely by medication, there are some positive indications from the use of malic acid, along with other elements 
that counteract the harmful effect on dental enamel. In general, lubrication of oral mucous membrane reduces the 
symptoms, although the effects are short-lived.
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Introduction
The total or partial loss of saliva causes serious oral 
consequences, manifesting as an uncomfortable feel-
ing of dry mouth (xerostomia) and presenting numer-
ous signs and symptoms mainly in the mucous mem-
branes, lips, tongue, salivary glands and teeth (Fig. 1) 
(1,2). In the majority of cases, dry mouth is caused by 
hypofunction of the salivary glands, acute or chronic, 
with or without xerostomia. In other cases, xerostomia 
is not accompanied by an actual loss of saliva (3). In 
older people, the most common cause is the use of medi-
cations with potential xerostomic effects, mainly anti-
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cholinergic, sympathomimetic, sedative-hypnotics, opi-
ates, antihistamines and muscle relaxants (4). In other 
situations, a dry mouth is mainly due to the radiation 
received by patients with cancer in the head / neck area 
or in patients with certain autoimmune diseases such as 
Sjögren’s Syndrome.
Despite the different etiological origins of dry mouth, 
the available treatment does not differ from one situa-
tion to another, except in cases of drug-induced xeros-
tomia, in which case, the therapeutic strategy is to ter-
minate the drug causing the sensation of dryness or 
substitute it for another with less xerostomic effect (5). 
So far there is no clear and effective treatment for every 
case, with different results and little scientific evidence 
in some cases, outlined in the latest systematic reviews 
published in 2011 (6) and 2013 (7) through the Cochrane 
Collaboration.
The aim of this study was to systematically review the 
latest available evidence regarding the treatment of dry 
mouth, regardless of the cause of the problem.
Material and Methods
For this review, we have followed PRISMA and the Co-
chrane Collaboration criteria (8,9) in terms of the for-
mulation of review questions, construction of the search 
strategy; definition of inclusion and exclusion criteria; 
location and study selection; assessment of the quality 
of work; data extraction and interpretation. After devel-
opment of the work protocol, the following review ques-
tion was posed: “In older subjects with xerostomia and/
or hyposalivation, regardless of etiology, what pharma-
cological or non-pharmacological treatments have posi-
tive results in terms of decreasing symptoms or increas-
ing salivary flow?”
The population included in the review were “older” 
subjects, complaining of dry mouth either from the 
consumption of possibly xerostomic drugs, or cases of 
patients diagnosed with Sjögren’s syndrome or other 
systemic diseases or those patients who have received 
radiation for head and neck cancer. Using the filters 
available in PubMed, the search was limited to “Clini-
cal Trials”, from 2006 to March 2015, in English, only 
in humans and using base data from MEDLINE. MeSH 
terms and the general search strategy were based on 
the following: (xerostomia OR Dry Mouth Syndrome) 
AND (OR Elderly Aged). After an initial selection of 
studies and after reviewing the title and abstract, the 
following were discarded; those that were not really 
clinical trials (although these would have been included 
as such by the computer system), literature reviews, sys-
tematic reviews and letters to the Director. Subsequent-
ly, a new filter was applied to the selected items to as-
sess the methodological quality. To do this we used the 
“Oxford Quality Scale” tool that gives scores between 
0-5 depending on the testing method of randomization, 
blind testing and loss assessment (10). The studies have 
been divided into three categories: 1) clinical trials that 
tested pharmacological treatments like pilocarpine 
or cevimeline; 2) clinical trials that tested other non-
pharmacological or artificial saliva products; 3) clinical 
trials that tested alternative treatments like acupuncture 
or electro-stimulation.
Functional alterations in: 
• Chewing 
• Flavour 
• Swallowing 
• Speaking 
Increased susceptibility to the occurrence of: 
• Caries 
• Gingivitis 
• Spontaneous bleeding  
• Periodontitis 
• Oral and oropharyngeal infections  
• Halitosis 
• Ulcers 
• Dental plaque formation 
Morphological changes: 
• Dry lips 
• Absence of saliva on the floor of the mouth 
• Pale and cracked oral mucosa 
• Filiform papilla atrophied and erythematous mucosa on the back of the tongue 
Other manifestations: 
• Pain 
• Dry eyes, skin, nose, throat 
• Difficulty to wear dental prosthesis 
!Fig. 1. Signs and symptoms of hyposalivation in the oral cavity.
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Results
In the initial search of the Medline database, a total of 
9,275 references were obtained (Fig. 2). After the first 
filter, a total of 351 papers were obtained. During the 
review of the titles and abstracts of these papers the fol-
lowing were discarded: those that were not really de-
signed as a clinical trial; review papers; letters to the 
editor and any duplicates. After classification by type 
of treatment that was being tested, 26 studies evaluat-
ing various drug treatments were identified, another 
20 were testing other non-pharmacological commer-
cial products or artificial saliva products and 12 were 
testing alternative treatments. Finally, the 58 selected 
works were analysed in depth and after applying the 
scale proposed by Jadad et al. (Oxford Quality Scale) 
(10), a total of 26 well-designed clinical trials with score 
4 or 5 were identified (Tables 1 and 1 Continue-3). The 
final 26 studies were reassessed in duplicate by two in-
vestigators, agreeing the score received where there was 
any discrepancy between the two. Few studies showed 
how the sample size was calculated, with the selected 
populations being between 20 and 570 individuals.
- Trials related to drug treatment.
A total of 14 clinical trials were identified, a priori prop-
erly randomized, double-blind, where there were given 
reasons for the possible loss of subjects after the test 
(except for Kim JH et al. (11) (Table 1 and 1 Contin-
ue). Therefore, these selected trials obtained the high-
est score according to the Oxford Quality Scale. The 
remaining studies were not selected mainly because 
they were not designed as clinical trials, were not well 
controlled or the authors gave no information either on 
blind testing or the randomisation processes, so the risk 
of bias was considerably increased. Among the selected 
studies, as many crossover trials were found in the ex-
perimental group as in the trials with two or three paral-
lel groups. Most were testing cholinergic agents (mus-
carine agonists) such as pilocarpine (11-15) cevimeline 
(16,17) and bethanechol (18) and the rest checked the 
efficacy of drugs or agents such as malic acid (19-21) 
or physostigmine (22). Finally, two studies analysed 
the improvement of symptoms of dry mouth in patients 
with pathologies such as Sjogren’s Syndrome, acting di-
rectly on the pathophysiology of the disease, with spe-
cific monoclonal antibodies such as Rituximab (23) or 
Rebamipide (24), drugs derived from fluoroquinolone 
Fig. 2. PRISMA flow chart to demonstrate the methodology applied to selected articles.
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with a protective action for gastric mucosa among oth-
ers. Three of the selected trials evaluated the action of 
the intervention months after the application of the drug 
treatment. The rest were carried out only to the end of 
the intervention, with no follow-up.
Five of the trials published at this time focused on sub-
jects irradiated for head and neck cancer (12-15,17,18). 
In these cases, despite obtaining improved on stimu-
lated and unstimulated salivary flow, not all had clearly 
improved symptoms of dry mouth. The dose of 5 mg 
pilocarpine four times daily was the most common and 
most effective, especially when the tablets were allowed 
to dissolve in the mouth, showing no significant adverse 
effects of this treatment. The way of administering the 
drug during or after radiation and the different doses 
made it difficult to compare or draw general conclu-
sions from these studies. The study of Burlage et al. 
with pilocarpine versus a placebo has been revised with 
longer follow-up and with a larger sample size (15). The 
use of cevimeline (16,17) and bethanechol (18) also had 
positive results in salivary flow as did the surgical trans-
position of the submandibular gland compared with 
treatment with pilocarpine (12). The only selected study 
where biological therapy with rituximab was used also 
had a large sample size and 3 months follow-up (23).
Of the five works selected and carried out on patients 
with Sjögren’s Syndrome (14,16,21,23,24), only that 
published by CH Wu et al. (14) showed positive results 
both in symptoms and in sialometry, in this case testing 
pilocarpine in doses of 5 mg, four times daily. The other 
studies, testing with rituximab (23), malic acid (21), re-
bamipide (24) or cevimeline (16) showed no clear signif-
icant changes which would warrant or support the idea 
of using these drugs to treat the underlying disease or its 
consequences. Only in the study published by KC Le-
ung et al. (16), were the symptoms were slightly better 
in the experimental group though sialometry was not.
Finally, in published trials on people with drug-induced 
xerostomia (11,19,20) or unknown causes (22), the re-
sults were mixed. In the study of Gómez-Moreno et al. 
on patients taking antidepressants (20) and antihyper-
tensive (19), using a spray of 1% malic acid improved 
both symptoms of dry mouth and salivary flow. The ef-
fect was also seen when the drug Physostigmine as a 
parasympathometic was used at doses of 1.8 mg / day 
and without significant adverse effects (22).
- Trials related to non-pharmacological treatment.
The studies that were not included in this section pre-
sented a low level of evidence through inadequate de-
sign. Where these studies were of a crossover design, 
they were excluded because many were not randomized; 
inclusion criteria was not mentioned or was very vague; 
there was no explanation about dropouts or losses or 
they were not double-blind. In other cases, the sample 
size was particularly low. Finally, eight successfully de-
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signed studies were identified, using artificial saliva or 
salivary substitutes in patients with xerostomia and two 
where the efficacy of oral supplementation for improv-
ing the signs and symptoms of dry mouth (Table 2 and 
2 Continue) were tested.
In four of the studies, an assessment of the effect of 
Biotene / Oral Balance®, an enzymatic system with an 
antimicrobial effect based on glucose oxidase, lactoper-
oxidase, lysozyme and lactoferrin glucose, was made. In 
the study of Gil Montoya et al. (25) it was tested against 
a placebo, evaluating dry mouth symptoms and showing 
no differences between the two groups. In the study by 
López-Jornet et al. (26) it is compared with a mouthwash 
with triclosan (antiseptic) and remineralising ingredients, 
such as fluorides and mineral salts. An improvement of 
symptoms was found with the triclosan mouthwash and 
also a significant decrease of cariogenic bacteria. Mc 
Millan et al. (27) compared the effect of Biotene / Oral 
Balance® against the efficacy of an intraoral appliance to 
maintain lubrication of the oral mucosa. A significant im-
provement was observed in the symptoms of dry mouth 
in the Oral Balance group whilst patients with the in-
traoral device reported severe discomfort. Finally, in the 
study by Kerr et al. (28) where muco-adhesive discs with 
lubricants and antimicrobial agents (glucose oxidase, lys-
ozyme and lactoferrin) were tested versus placebo discs, 
slight improvements were noted but without significant 
differences between the two groups.
Frost et al. (29) had already tried to maintain oral lubrica-
tion with water or artificial saliva by means of an intraoral 
device and compared this with a group who chewed sug-
arless gum. They concluded that the oral device produced 
difficulties on speech and cariogenic growth of germs. In 
the study by Ship et al. (30) a crossover study was car-
ried out on 40 adult patients taking multiple drugs with 
xerostomic effects (2 groups of 20 subjects) where the pa-
tients were given a mouthwash based on olive oil, betaine 
and xylitol. A quantitative sialometry was performed and 
some increase in salivary flow rates were observed when 
using the product which reduced discomfort. There were 
no significant adverse effects.
Morales-Bozo et al. (31) tested with a mouthrinse con-
taining xylitol, sodium fluoride, cetylpyridinium and 
mint over another with propylene glycol, aloe vera, 
glycerin, and citric acid. Both mouthwashes improved 
the symptoms of dry mouth. Femiano et al. (32) in their 
study compared three groups of water-based artificial 
saliva, one containing cellulose, sorbitol and mineral 
salts, another with 3% citric acid and the last group 
with water. Changes were not observed in the rates of 
unstimulated salivary flow. However, there was an im-
provement in the symptoms of the group with artificial 
saliva and citric acid, the latter being where the effects 
were longer lasting.
Finally, in connection with oral supplements in the study 
by Flink et al. (33), the effect of iron supplements (oral) 
on unstimulated salivary flow rate versus a placebo was 
investigated in patients diagnosed with hyposalivation 
and low iron. These supplements had no significant in-
crease in the subjects’ secretion of unstimulated saliva. 
Likewise, other authors (34) compared Omega-3 and 
vitamin E supplements against wheat germ oil in Sjö-
gren’s Syndrome patients. Both rates increased salivary 
secretion (stimulated and unstimulated) without obtain-
ing higher significant benefits in the supplements with 
Omega 3 and vitamin E.
- Trials related to alternative treatment.
Taking the criteria for inclusion into consideration, 
only two studies were selected in this review within the 
selected dates (Table 3). The most common reason for 
exclusion of the remaining studies was that the study 
design was not compatible with a clinical trial.
Strietzel et al. (35) examined the efficacy of intraoral 
electrostimulation in symptoms and signs of xerostomia 
in patients with this condition. This technique showed 
a significant improvement in the short term (3 months) 
in symptoms such as frequency and severity of dry-
ness and difficulty swallowing and in the long-term (5 
months) in symptoms such as frequency and severity of 
dryness, oral discomfort, difficulty in sleeping and talk-
ing and the rate of unstimulated salivary secretion.
Other authors such as Simcock et al. (36) examined the 
efficacy of acupuncture compared with the delivery of 
two sessions of oral education (advice on diet products 
to relieve xerostomia and oral hygiene) in patients treat-
ed with radiotherapy. After 8 weeks of application, the 
patients treated in this group had a significant improve-
ment in symptoms (dry mouth, sticky saliva, need to 
drink to swallow food and getting up at night needing a 
drink). There were no differences in rates of stimulated 
or unstimulated salivary secretion.
Discussion
According to the results of the trials included in this 
review, the efficacy of different therapeutic strategies 
for the control of symptoms and signs derived from 
hyposalivation, regardless of their origin, are still not 
strong enough to recommend a particular treatment, ei-
ther pharmacological or not. Most treatments tested and 
used in patients with xerostomia temporarily improve 
symptoms and, to some extent, salivary flow, but with-
out medium or long term control in all cases, making 
the use of such therapeutical strategies difficult and un-
predictable. In general, the sample sizes of the studied 
clinical trials were small or moderate and short-lived, 
especially the non-pharmacological treatment trials 
and alternative treatments, which also call for solid and 
consolidated results. Ten of the 26 selected studies were 
crossover trials, a design that allows more efficiency in 
determining patient preferences.
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When hyposalivation and its oral consequences comes 
from irradiation of the parenchyma, pilocarpine is the 
most-used parasympathomimetic drug with the best re-
sults, but always where there is some residual function 
of the parenchyma.  Studies were carried out using dif-
ferent doses (3 and 5 mg), different times of use (during 
or after radiotherapy) and different dispensing means 
(swallowing or dissolving tablets in the mouth or rins-
es). Localised treatment with pilocarpine by dissolving 
tablets (13) or rinses to 0.1% seems more effective than 
systemic administration (11), although further studies 
to strengthen the scientific evidence and to determine 
the necessary dose of topical pilocarpine in order to re-
ally improve the effectiveness of this system. Studies 
with a longer follow-up to determine long-term effects 
were conducted with pilocarpine, such as the work pub-
lished by Burlage et al. (15) where it was tested against 
a placebo or where Jha et al. compared it with the sur-
gical transposition technique (12). Trials with other 
drugs such as bethanechol and cevimeline have also 
been successful in improving the levels of salivary flow 
and symptoms in this type of patient (16,18). However, 
they have not been tested against pilocarpine so it is not 
known whether they improve the cost / benefit ratio. 
None of the studies in this review observed the system-
ic adverse effects associated with pilocarpine or other 
parasympathomimetic drugs, such as sweating, nausea, 
fever or diarrhoea. This is probably due to the short 
follow-up period of the studies reviewed (37), except for 
that of Jham et al. (18) where patients were reviewed for 
two months after completion of radiotherapy.
In the case of Sjögren’s Syndrome there has also been a 
lack of important developments in recent years in terms 
of drug treatment. Pilocarpine again remains the only 
drug used in trials showing clear improvements in sali-
vary flow and symptoms (14). Trials with rebamipide and 
malic acid showed no significant differences from their 
placebos. Only in the work published by Leung et al. (16) 
was an improvement of symptoms observed in the ex-
perimental group, though not in the sialometry. This fact, 
according to some authors, is due to the effect of para-
sympathomimetic drugs on the minor salivary glands, 
rather than on the parenchyma of the major salivary 
glands, causing a major lubrication of the oral mucosa 
without resulting in a real increase in the total amount 
of saliva secreted (13). Emerging biological therapies in 
recent years have not so far produced anticipated results 
for Sjögren’s Syndrome. Specifically, rituximab, a mono-
clonal antibody with proven activity in diseases such as 
lymphoma or rheumatoid arthritis, has not always proven 
to be more effective than the placebo itself (23) without 
knowing in which patients this and other biological thera-
pies obtained good results (38). However, this latter was 
the only trial that followed patients for 36 months to iden-
tify the results of long-term intervention.
Few studies focused on the pharmacological treatment 
of xerostomia where the cause is due to the consumption 
of drugs, in addition to not knowing what would happen 
in the long-term and to medium sample sizes. The use 
of malic acid with fluoride and xylitol, both spray and 
tablets, have been successful in terms of symptoms and 
sialometry (19-21). However, more tests are needed with 
larger sample sizes and where products are applied for 
a longer period to assess the possible adverse effects of 
acid on tooth enamel. A new approach from Khosra-
vani et al. (22) assessed the capacity of physostigmine 
(a plant-derived alkaloid acetylcholinesterase inhibi-
tor) as a sialogogue drug in patients with xerostomia of 
unknown cause (patients not suffering any disease that 
would justify it like Sjögren , sarcoidosis, etc), or who 
had received radiation and who had not been labelled 
a priori as taking xerostomic drugs. In these cases (20 
subjects), a clear improvement was observed in symp-
toms and salivary volume secreted in the following 2-3 
hours after application of a solution of physostigmine.
In all the studies analysed where a mouthwash was used, 
the symptoms improved even after using water or a pla-
cebo (25-27,30,31). However, no short to medium term 
monitoring was carried out so the durability of the treat-
ment applied is unknown. It seems logical that in these 
cases the treatments applied should continue as long 
as the etiology exists (xerostomic drugs, autoimmune 
syndromes, etc). This shows that single lubrication of 
the oral mucosa is positive with respect to xerostomia. 
It highlights the study of Morales-Bozo, which has an 
acceptable sample size, a crossover design but a short 
follow-up after the application of a mouthwash. In both 
working groups the results were very positive (31). The 
use of intraoral devices such as a deposit has not been 
proven useful (29). The problem is that they do not last 
long enough to produce an improvement in the quality 
of life of these patients. However, the effect of using cit-
ric acid in a salivary substitute does seem to provide in-
creased and improved comfort for somewhat longer pe-
riods (31,32). These salivary substitutes are often used 
when the xerostomia has been caused by the irreversible 
destruction of the salivary hyposialia by parenchyma or 
because sialagogues can not be administered to patients 
because of the adverse effects (26). Lubricants and sali-
vary substitutes are only a useful palliative treatment 
when they are administered continuously.
The drawbacks shown with intraoral devices for stor-
ing artificial saliva has also been a trend in the studies 
reviewed here. These devices produce inconvenience 
and discomfort for patients and could even alter the oral 
environment favouring the growth of cariogenic bacte-
ria. Conversely, use of a mouthwash with triclosan had 
the opposite effect by decreasing such microorganisms. 
In an interesting study carried out some time prior to 
our review (39), the application of a reservoir of artifi-
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cial saliva seemed to be a good therapeutic alternative 
for improving the symptoms of xerostomia because, 
although no significant differences were found in the 
total score in the questionnaire assessing quality of life, 
the reservoir in itself reduced the number of impacts 
affecting the daily life of the patient. The failure to find 
corresponding differences in the total score could be 
due to the short follow-up period of the study (1 month) 
since the modifications made in the questionnaire and 
application form affect the mathematical properties of 
the original questionnaire.
The similarity in oral symptoms presented by patients 
with iron deficiency and in patients with xerostomia and 
/ or hyposalivation and the known role of iron in cellular 
metabolism may make iron administration a therapeutic 
option for improving hyposalivation (40). However, it 
has been shown that this treatment is not effective. Oral 
supplementation with Omega-3 and vitamin E for pa-
tients with Sjögren’s Syndrome, however, could be ben-
eficial in improving salivary secretion rates (stimulated 
and unstimulated) (34). The result of such supplements 
were not significantly better than supplements with 
wheat germ oil though the reason for this may lie in the 
fact that the latter also had small amounts of Omega 3 
and vitamin E (34).
The use of alternative stimulating agents could be a 
good therapeutic option for the treatment of xerostomia 
/ hyposalivation because, in most cases, these have no 
side effects or those that have been described are lim-
ited. Among these alternatives, the oral electrostimula-
tion and acupuncture have shown to be effective treat-
ments to improve certain symptoms affecting patients 
with xerostomia (35,36). Oral electrostimulation had the 
added advantage that, even in patients who had a higher 
therapeutic challenge, being completely devoid of sali-
vary secretion capacity at baseline, showed improve-
ment in the rate of unstimulated salivary secretion. The 
two studies selected for this review had acceptable sam-
ple sizes and follow-ups of six and three months after 
completion of the intervention, reinforcing the results.
The inherent limitations of systematic reviews in general 
are also evident in our work. Despite performing an ini-
tial broad search strategy, with subsequent limitations, 
some tests may not have been identified. For example, 
those which do not describe their population as “eld-
erly” or those written in languages other than English. 
We recognize that these issues may incur potential bias 
for this review. Similarly, some studies in implementing 
the “Oxford Quality Scale” excessively or inadequately, 
may have been incorrectly selected or not, as a result of 
the publication description made by the author.
In short, as evidenced by the data found in the selected 
publications in this review, pilocarpine, the sialogogue 
drug, has produced the best results in patients with 
xerostomia due to radiation in head and neck cancer or 
diseases such as Sjogren’s Syndrome. In patients with 
purely drug-related dry mouth there is some positive 
evidence in the use of malic acid along with other el-
ements that counteract the harmful effects on dental 
enamel. In general, the lubrication of the oral mucosa 
reduces symptoms, although the effects are short-lived 
so far. It is necessary to conduct further trials, prefer-
ably crossover in design, with large sample sizes and 
long-term monitoring of the effects of the intervention.
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